Gefitinib vs Lazertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Gefitinib

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00020709 · Phase 3 · completed

SWOG S0023 registered 840 patients for chemoradiation and docetaxel consolidation; 243 of them were then randomized, double-blind, to gefitinib or placebo maintenance. The primary endpoint, overall survival, is a hard clinical outcome. An unplanned interim analysis stopped the randomized comparison, and survival was shorter with gefitinib than with placebo. The key result shown was recovered from the cited publication.

Next expected readout: July 2027 · NCT03333343 (registry estimate)

Reported efficacy

Overall Survival (From date of registration to date of death due to any cause, assessed up to 10 years); Progression-free survival (From date of registration to date of first observation of progressive disease, death due to any cause, assessed up to 10 years): Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 (missed)

Result source: NCT00020709

Lazertinib

Marketed by Johnson & Johnson and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04248829 · Phase 3 · completed

The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).

Next expected readout: December 2026 · NCT05463224 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)

Result source: NCT04487080

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGefitinibLazertinib
PFS, median5.4 vs 5.4±0 vs placebon 133NCT01544179
14 other results
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results
OS, median14.8 vs 17.2−2.4 vs placebon 133NCT01544179
8 other results
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396
ORR31.6% vs 34.1%−2.5 vs placebon 133NCT01544179
5 other results
  • 55% vs 28.6% n 60 · Phase 1/2 · primary NCT02039674
  • 29.5% n 44 · Phase 1/2 · primary NCT02039674
  • 45.2% vs 33.3% 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396
Duration of response, median—Not posted · NCT0365354619.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396

PFS, median

Gefitinib
5.4 vs 5.4±0 vs placebon 133NCT01544179
14 other results
Lazertinib
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results

OS, median

Gefitinib
14.8 vs 17.2−2.4 vs placebon 133NCT01544179
8 other results
Lazertinib
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396

ORR

Gefitinib
31.6% vs 34.1%−2.5 vs placebon 133NCT01544179
5 other results
  • 55% vs 28.6% n 60 · Phase 1/2 · primary NCT02039674
  • 29.5% n 44 · Phase 1/2 · primary NCT02039674
  • 45.2% vs 33.3% 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
Lazertinib
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396

Duration of response, median

Gefitinib
—Not posted · NCT03653546
Lazertinib
19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Gefitinib: 9 of 9 rows · Lazertinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGefitinib
Rows use multiple source trials
Lazertinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
84.2% (n=133) vs 78.8% (n=132) placeboa,b,c
NCT01544179 · Phase 3 · registry result, not featured evidence
1 other source trial
83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
93.9% (n=196) vs 93.9% (n=197) Gefitnib240 mga,b,c
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control
responder rate · % of participants
No placebo or comparator arm
58.3% (n=12)500 mg + 250 mgd,a,b,c
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
60% (n=15)240 mgd,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
53.8% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
29.5% (n=44)a,b,c
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
2 other source trials
33.3% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
33.3% (n=12)500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
26.7% (n=15)240 mgd,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
19.22 monthse,a,b,c
NCT01203917 · Phase 4 · registry result, not featured evidence
2 other source trials
10.22 months*
NCT01530334 · Phase 2 · registry result, not featured evidence · converted to months from 311 days as posted
10 months
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
9.1 months240 mgd,e,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
9.72 monthsd,e,a,b,c
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more dose
6.97 months
NCT01203917 · Phase 4 · registry result, not featured evidence
3.1 months240 mgd,e,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
4.2 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Dropout rate
40.6%f
NCT00322452 · Phase 3
show 40 more results
—250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
33.6%Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
54.7%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
9.6%
NCT00608868 · Phase 4 · registry result, not featured evidence
—250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
47.4%Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
0.8%
NCT00049543 · Phase 3 · registry result, not featured evidence
62.3%
NCT02856893 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
83.6%
NCT01530334 · Phase 2 · registry result, not featured evidence
0%
NCT00824746 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT00264498 · Phase 2 · registry result, not featured evidence
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
7.7%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
44.9%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
78.1%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
75%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.5%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
80.2%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT00322452 · Phase 3
show 40 more results
—250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
—Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
6.1%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
0.6%
NCT00608868 · Phase 4 · registry result, not featured evidence
—250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
0%Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
—
NCT00049543 · Phase 3 · registry result, not featured evidence
3.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
4.9%
NCT01530334 · Phase 2 · registry result, not featured evidence
—
NCT00824746 · Phase 2 · registry result, not featured evidence
—
NCT00264498 · Phase 2 · registry result, not featured evidence
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
3%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
9.7%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
—Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
—320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Serious AEs
18.1%f
NCT00322452 · Phase 3
show 40 more results
19.6%250 mg
NCT01203917 · Phase 4 · registry result, not featured evidence
—Gefitinib
NCT01203917 · Phase 4 · registry result, not featured evidence
6.8%250 mg
NCT00770588 · Phase 4 · registry result, not featured evidence
16.2%
NCT00608868 · Phase 4 · registry result, not featured evidence
28.8%250 mg
NCT01544179 · Phase 3 · registry result, not featured evidence
—Gefitinib
NCT01544179 · Phase 3 · registry result, not featured evidence
13.7%
NCT00049543 · Phase 3 · registry result, not featured evidence
17%
NCT02856893 · Phase 2 · registry result, not featured evidence
42.9%800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
60%600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
22.6%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
40.4%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
37.5%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
28.6%200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
71.4%200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
20%100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
17.2%
NCT01530334 · Phase 2 · registry result, not featured evidence
—
NCT00824746 · Phase 2 · registry result, not featured evidence
—
NCT00264498 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
61.5%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
50%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
36.4%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
41.9%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
66.7%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
41.7%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
26%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
48.7%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
35.2%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
52.1%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
32.3%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
66.7%240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
46.2%320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
f
rash 50.7%
diarrhoea 45%
dry skin 23.7%
NCT00322452 · Phase 3
show 37 more results
250 mg
rash 46.7%
diarrhoea 29%
asthenia 11.2%
NCT01203917 · Phase 4 · registry result, not featured evidence
250 mg
rash 49.7% (placebo 9.5%)
serious hepatic dysfunction 29.3% (placebo 10.8%)
diarrhoea 25.2% (placebo 8.8%)
NCT00770588 · Phase 4 · registry result, not featured evidence
rash 33.8%
diarrhoea 26%
pruritus 17.5%
NCT00608868 · Phase 4 · registry result, not featured evidence
250 mg
nausea 63.6% (placebo 60.6%)
decreased appetite 48.5% (placebo 34.1%)
vomiting 40.9% (placebo 32.6%)
NCT01544179 · Phase 3 · registry result, not featured evidence
rash 67.1% (placebo 27.2%)
diarrhea 62.2% (placebo 30.9%)
fatigue 54.2% (placebo 53.5%)
NCT00049543 · Phase 3 · registry result, not featured evidence
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
800 mg Cap QD
vomiting 100%
nausea 85.7%
decreased appetite 57.1%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
600 mg Cap BID
cough 60%
decreased appetite 60%
hypoproteinaemia 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 43.4%
anaemia 34%
oedema peripheral 28.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 58.3%
blood bilirubin increased 41.7%
amylase increased 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap QD
nausea 50%
cough 33.3%
oedema peripheral 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
nausea 55.3%
oedema peripheral 44.7%
decreased appetite 40.4%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
decreased appetite 37.5%
diarrhoea 37.5%
headache 37.5%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap BID
diarrhoea 75%
hypoalbuminaemia 75%
anaemia 50%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap QD
back pain 57.1%
rash 42.9%
vomiting 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Tab BID
nausea 71.4%
dermatitis acneiform 57.1%
cystitis 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
100 mg Cap QD
constipation 60%
pruritus 60%
amylase increased 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
diarrohea 27.6%
rash 15.5%
vomiting 15.5%
NCT01530334 · Phase 2 · registry result, not featured evidence
diarrhoea 53.8%
dyspnoea 34.6%
nausea 30.8%
NCT00264498 · Phase 2 · registry result, not featured evidence
200 mg
decreased appetite 32.1% (placebo 27.4%)
fatigue 25% (placebo 58.1%)
cough 21.4% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
nausea 72.9% (placebo 59.7%)
fatigue 69.5% (placebo 58.1%)
constipation 54.2% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
alopecia 61.5% (placebo 3.2%)
cough 53.8% (placebo 27.4%)
decreased appetite 53.8% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 91.7% (placebo 58.1%)
constipation 58.3% (placebo 40.3%)
anaemia 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100% (placebo 58.1%)
actinic keratosis 33.3% (placebo 1.6%)
back pain 33.3% (placebo 12.9%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
arthralgia 66.7% (placebo 29%)
chills 66.7% (placebo 4.8%)
cough 66.7% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 61.5% (placebo 40.3%)
fatigue 61.5% (placebo 58.1%)
alopecia 53.8% (placebo 3.2%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 81.8% (placebo 40.3%)
alopecia 72.7% (placebo 3.2%)
fatigue 72.7% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 66.7% (placebo 40.3%)
nausea 58.3% (placebo 59.7%)
fatigue 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 41.7% (placebo 40.3%)
vomiting 41.7% (placebo 32.3%)
cough 33.3% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 66.7% (placebo 30.6%)
fatigue 58.3% (placebo 58.1%)
cough 50% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 57.1% (placebo 30.6%)
pruritus 42.9% (placebo 11.3%)
rash 28.6% (placebo 16.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 48.5% (placebo 58.1%)
constipation 27.3% (placebo 40.3%)
arthralgia 24.2% (placebo 29%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.7% (placebo 58.1%)
alopecia 58.3% (placebo 3.2%)
constipation 58.3% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
500 mg + 250 mg
diarrhoea 83.3%
dyspnoea exertional 41.7%
fatigue 41.7%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
500 mg + 250 mg
diarrhoea 58.1%
oedema peripheral 38.7%
amylase increased 35.5%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
300 mg + 250 mg
amylase increased 66.7%
diarrhoea 66.7%
blood alkaline phosphatase increased 50%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
diarrhea 41.7%
dysphagia 33.3%
rash 33.3%
NCT00328562 · Phase 1 · registry result, not featured evidence · combination
240 mgg
paraesthesia 39.3%
rash 36.2%
pruritus 26.5%
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
paronychia 68.4%
infusion related reaction 62%
rash 61.8%
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
rash 44.6%
diarrhoea 31.9%
paronychia 28.6%
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
neutropenia 65.8%
thrombocytopenia 59.3%
infusion related reaction 54%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
infusion related reaction 56.9%
neutropenia 56.2%
nausea 44.6%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
240 mg
anaemia 46.7%
diarrhoea 46.7%
aspartate aminotransferase increased 26.7%
NCT04075396 · Phase 1/2 · registry result, not featured evidence
320 mg
nausea 61.5%
diarrhoea 53.8%
arthralgia 23.1%
NCT04075396 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 4 versus Phase 1/2.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gefitinib

Overall Survival 18.7 vs 16.9 placebo months250 mg
time to event · months
NCT00770588 · Phase 4 · registry result, not featured evidence
show 6 more results
17.25 vs 19.48 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
34.5 vs 21.1 placebo months
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
18.8 vs 17.4 Carboplatin/Paclitaxel months
NCT00322452 · Phase 3
14.8 vs 17.2 placebo months
NCT01544179 · Phase 3 · registry result, not featured evidence
NA vs NA Gefitinib months
NCT02856893 · Phase 2 · registry result, not featured evidence
23 vs 35 placebo months
NCT00020709 · Phase 3 · sponsor-reported, not registry data
ORR 23.6% (n=148) vs 0.7% (n=148) placebo250 mg
event count · % of participants
NCT00770588 · Phase 4 · registry result, not featured evidence · converted to % from 35 Participants as posted
show 1 more result
43% (n=609) vs 32.2% (n=608) Carboplatin/Paclitaxel*
NCT00322452 · Phase 3 · converted to % from 262 Participants as posted
ORR 69.8% (n=106)
responder rate · % of participants
No placebo or comparator arm
% Responders
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more result
50% (n=106)
% Responders
NCT01203917 · Phase 4 · registry result, not featured evidence
Disease Control 90.6% (n=106)
responder rate · % of participants
No placebo or comparator arm
% Controlled
NCT01203917 · Phase 4 · registry result, not featured evidence
show 1 more result
88.7% (n=106)
% Controlled
NCT01203917 · Phase 4 · registry result, not featured evidence
ORR 31.2% (n=138)
absolute value · percentage points
No placebo or comparator arm
NCT00608868 · Phase 4 · registry result, not featured evidence
FACT-L Improvement 41% (n=94)
responder rate · % of participants
No placebo or comparator arm
NCT00608868 · Phase 4 · registry result, not featured evidence
Overall Survival 0.52% (n=251) vs 0.57% (n=252) placebo @ 260wk
absolute value · percentage points
NCT00049543 · Phase 3 · registry result, not featured evidence
Disease-free Survival 0.49% (n=251) vs 0.56% (n=252) placebo @ 260wk
absolute value · percentage points
NCT00049543 · Phase 3 · registry result, not featured evidence
PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Progression 19.48 vs 10.81 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

Lazertinib

Overall Survival 25% (n=196) vs 32.5% (n=197) Gefitnib240 mg
event count · % of participants
Death
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 · converted to % from 49 Participants as posted
Duration of Response NA months240 mg
time to event · months
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
2.8 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Tumor Size -5.37% (n=14)240 mg
percent change · % of baseline
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
9.56% (n=12)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gefitinib's landscape · Lazertinib's landscape